Literature DB >> 19574670

Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.

F D Shah1, S N Shukla, P M Shah, H K Shukla, P S Patel.   

Abstract

BACKGROUND: Invasion and metastasis are the most strenuous problems in the management of breast cancer. These events require diverse proteolytic enzymes, among which MMP-2 and MMP-9 play a significant role in degradation of type IV collagen, the major component of the basement membrane. Therefore, the major objective of the study is to evaluate the clinical usefulness of MMP-2 and MMP-9 with respect to malignant tumor growth, invasion, and metastasis in breast cancer.
MATERIALS AND METHODS: Gelatin zymography was performed on 157 tissue extracts of malignant and adjacent normal breast tissues as well as negative and positive lymph nodes from 49 breast cancer patients. Statistical analysis was carried out using SPSS statistical software (version 10).
RESULTS: ProMMP-2 levels were significantly higher in adjacent normal tissues. Active MMP-2 and MMP-9 levels were higher in malignant breast tissues. Activation ratios of MMP-2 and MMP-9 were significantly higher in malignant breast tissues and in patients with lymph node metastasis. ProMMP-2, active MMP-2, and active MMP-9 could significantly discriminate between malignant and adjacent normal breast tissues. The MMP-2 activation ratio showed significant discriminatory efficacy between patients with and without lymph node metastasis and significant association with increased risk of lymph node metastasis in node-negative patients.
CONCLUSION: The results indicate significant clinical utility of these proteolytic enzymes in malignant tumor growth, invasion, and metastasis in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574670     DOI: 10.4103/0019-509X.52953

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  22 in total

1.  Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer.

Authors:  Diaa Al-Raawi; Helal Abu-El-Zahab; Mohamed El-Shinawi; Mona Mostafa Mohamed
Journal:  Int J Clin Exp Med       Date:  2011-10-11

Review 2.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

3.  Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer.

Authors:  Ragini D Singh; N Haridas; Jayendra B Patel; Franky D Shah; Shilin N Shukla; Pankaj M Shah; Prabhudas S Patel
Journal:  Indian J Clin Biochem       Date:  2010-08-25

Review 4.  Glycosylation: a hallmark of cancer?

Authors:  Bhairavi N Vajaria; Prabhudas S Patel
Journal:  Glycoconj J       Date:  2016-12-14       Impact factor: 2.916

5.  Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients.

Authors:  Irena Ranogajec; Jasminka Jakić-Razumović; Velibor Puzović; Jelka Gabrilovac
Journal:  Med Oncol       Date:  2011-05-25       Impact factor: 3.064

6.  Tissue inhibitor of metalloproteinase-2 regulates matrix metalloproteinase-2-mediated endothelial barrier dysfunction and breast cancer cell transmigration through lung microvascular endothelial cells.

Authors:  Qiang Shen; Eugene S Lee; Robert L Pitts; Mack H Wu; Sarah Y Yuan
Journal:  Mol Cancer Res       Date:  2010-06-22       Impact factor: 5.852

7.  Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells.

Authors:  Abitha Jacob; Jian Jing; James Lee; Pepper Schedin; Simon M Gilbert; Andrew A Peden; Jagath R Junutula; Rytis Prekeris
Journal:  J Cell Sci       Date:  2013-07-31       Impact factor: 5.285

8.  Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue.

Authors:  Mohammad A Mohammad; Ahmed A Zeeneldin; Zakaria Y Abd Elmageed; Ebtsam H Khalil; Said M E Mahdy; Hayat M Sharada; Sabry K Sharawy; Abdel-Hady A Abdel-Wahab
Journal:  Mol Cell Biochem       Date:  2012-04-18       Impact factor: 3.396

9.  Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene.

Authors:  Lisa Becks; Misty Prince; Hannah Burson; Christopher Christophe; Mason Broadway; Ken Itoh; Masayuki Yamamoto; Michael Mathis; Elysse Orchard; Runhua Shi; Jerry McLarty; Kevin Pruitt; Songlin Zhang; Heather E Kleiner-Hancock
Journal:  BMC Cancer       Date:  2010-10-08       Impact factor: 4.430

10.  Body fluid MMP-2 as a putative biomarker in metastatic breast cancer.

Authors:  Sewon Noh; Jae-Joon Jung; Minkyu Jung; Ki-Hyang Kim; Ha-Young Lee; Brandon Wang; Joanna Cho; Tae Soo Kim; Hei-Cheul Jeung; Sun Young Rha
Journal:  Oncol Lett       Date:  2012-01-03       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.